ASX Release
20 March 2025

ASX code: PIQ

Investor Presentation
Proteomics International to present at Broker Meets Biotech

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to attendees of the WA Life Sciences Broker Meets Biotech event, Perth on 20th March 2025.

Authorised by Dr Richard Lipscombe (Managing Director) and Dr James Williams (Non-Executive Chairman) on behalf of the Board of PIQ.

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)
Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
Investor Relations
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

ASX: PIQ

Proteomics International
LABORATORIES LTD

Broker Meets Biotech

Investor Presentation
- suite of diagnostic tests primed for launch

Perth, 20th March 2025

Dr. Richard Lipscombe
Managing Director

Disclaimer

This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ).

You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or not to seek to purchase the shares of the Company. This is not an offer to subscribe for securities in the Company.

The Presentation may contain quantitative statements of anticipated future performance such as projections, forecasts, calculations, forward-looking statements or estimates all of which are based on certain assumptions (Forward Looking Statements). The Forward Looking Statements may involve subjective judgements and are based on a large number of assumptions and are subject to significant uncertainties and contingencies, many of which are outside the control of the Company and may not prove to be correct.

No representation or warranty is made that any Forward Looking Statements will be achieved, or occur, or that the assumptions upon which they are based are reasonable or the calculations from which they have been derived are correct. Actual future events may vary significantly from the Forward Looking Statements. Each Recipient should undertake their own independent review of the Forward Looking Statements, including the assumptions on which they are based and the financial calculations from which they are derived.

Proteomics International Laboratories Ltd

ASX: PIQ

A medical technology company at the forefront of precision diagnostics

Launching four first-in-class tests driven by a proprietary platform technology:

PromarkerD — *Diabetic Kidney Disease* — COMMERCIALISATION

- A novel and accurate blood test for predicting the onset of chronic kidney disease in type 2 and type 1 diabetes (DKD)
- 10.5% of adults worldwide currently have diabetes with **32 million in the US alone – currently 1 in 2 will develop DKD**
- US reimbursement price set at USD $391

PromarkerEndo — *Endometriosis* — DEVELOPMENT / COMMERCIALISATION

- First-in-class blood test identifies all stages of endometriosis with high accuracy (sensitivity and specificity up to 96%)
- **Affects 1 in 9 women worldwide**; costs Australia alone over AUD $10bn p.a.
- Current average 7 years for diagnosis: **replaces diagnostic laparoscopy**

PromarkerEso — *Esophageal Cancer* — DEVELOPMENT / COMMERCIALISATION

- A novel blood test to diagnose esophageal cancer - clinical validation study identified 94% of patients with the disease
- **Caused by chronic acid reflux** (or 'GERD'), 1 in 20 cancer deaths worldwide are due to esophageal cancer
- **Replaces endoscopy/biopsy: 1.5 million per year in US**

OxiDx — *Oxidative Stress* — DEVELOPMENT / COMMERCIALISATION

- Groundbreaking results precisely identify muscle damage & assess recovery in high performance athletes; interest from thoroughbred horse racing
- In professional sports muscle damage accounts for 55% of injuries – **$1.2bn spent treating potentially avoidable injuries in Australia (2023)**

Corporate Overview

ASX: PIQ

Corporate Snapshot	
ASX code	PIQ
Market Capitalisation	A$65.5m
Cash (31 Dec 2024)	A$5.3m
Share Price (18 Mar 2025)	A$0.50
Shares on issue	131m
Revenue & other income – FY25	A$2.9m
Average Quarterly cash burn – FY25	A$1.5m

Financial and Corporate

- Top 40 Shareholders hold 41%
  - Directors are highly aligned with shareholders holding 13%
- **Revenue generating**
  - Bioanalytical service business helps offset cash burn
  - Launching four tests in 2025 to monetise PromarkerD, PromarkerEso, OxiDx & PromarkerEndo
- **Corporate**
  - Board renewal: Industry experienced Chair and NED appointed
  - Recruited senior executives to accelerate test commercialisation
- **State-of-the-art laboratories**
  - Specialist proteomics technology platform
  - Cutting edge facility with world leading accreditation: ISO 17025 (analytical) and ISO 13485 (manufacturing), expanding to include ISO 15189 (clinical testing)
  - US clinical reference laboratory established (CLIA certified)
  - Analytical services – pharmacokinetic (PK) testing & biosimilars
  - Headquartered on QEII Medical Campus, Perth, WA

Board of Directors

ASX: PIQ

Dr James Williams PhD (Melbourne), MBA (UWA), BSc, Hons (Aberdeen), GAICD, Non-Executive Chair

Accomplished manager, director, scientist and investor with experience covering all aspects of life-science technology translation. Involved from startup to commercialisation, including CEO, CTO, Director and Chair roles, of numerous biotech companies (including Dimerix (DXB.ASX) and iCeutica) which have resulted in five Food and Drug Administration (FDA) approved drugs, medical devices and diagnostics.

Dr Richard Lipscombe PhD (London), MA (Oxon), Co-Founder & Managing Director

Led the Company from foundation through listing in 2015 to today. Thirty years biotechnology experience in R&D and product commercialisation in commercial and academic entities. Technical expertise in chemistry, immunology, biomarker discovery & clinical proteomics.

Paul House GAICD, BCommerce (UWA), Non-Executive Director

Over 25 years with multi-national corporations, CEO of Imdex (ASX:IMD), prior role as MD of SGS India for 8 years. Previously held CFO and COO roles and was Senior Manager at a leading global management consultancy firm.

Neville Gardiner BBus (Accounting and Business Law) (Curtin), Non-Executive Director

Seasoned finance professional with over 30 years' experience providing corporate advice to Boards of public and private companies. He was Co-Founder and MD of Torridon Partners, an independent corporate advisory firm, which was acquired by Deloitte in 2016, where he became Partner in their M&A Advisory team.

Aaron Brinkworth GAICD, BHlthSc (ECU), Non-Executive Director (appointed 8 Nov 24)

Over a 22-year career at Gilead Sciences, Inc. (Nasdaq: GILD), he held senior commercial, patient access and strategic licensing roles. Mr Brinkworth has led Gilead's Asia Pacific commercial and access operations where he was responsible for developing high performing sales, marketing, and distribution networks across the region. Mr Brinkworth currently serves as non-executive Director for Resonance Health Ltd (ASX: RHT).

Commercialisation Team

ASX: PIQ

Phillip Prather
Chief Commercial Officer

Phillip brings extensive leadership in the global medical devices industry, particularly in developing new markets and successfully launching products for innovative companies including Cochlear, QIAGEN, Philips, Medtronic, and Leo Cancer Centre. His experience includes regulatory, quality, and market access across major medtech markets (EU, North America, APAC). Philip is responsible for global sales, marketing, and customer engagement activities.

Jacqueline Gray
Chief Financial Officer & Head of Corporate Development

Jacqueline has held senior leadership roles with global media and healthcare companies, including the Economist, BBC Worldwide, and Healthcare of Australia. More recently her focus has been with high growth, emerging businesses in medical technology, Software as a Service (SaaS), digital marketing and e-commerce. Jacqueline has experience in M&A, business restructuring, and managing businesses during disruption, downturn, and exponential growth.

Dr Pearl Tan
Head of Product Development

Pearl is responsible for the commercial delivery of the Promarker® pipeline. Since joining Proteomics International in 2014, Pearl has successfully led the manufacturing of the PromarkerD test, regulatory & PLA code submissions, and most recently the establishment of the Company's CLIA certified lab in the USA.

Dr Johan Conradie
Clinical Pathologist

Johan is a Chemical Pathologist with over 21 years of experience in clinical biochemistry and toxicology, and gained his FRCPA in 2008 and later completed an MBA at the University of Western Australia in 2019. Johan also serves as the Medical Director of Western Diagnostic Pathology. Johan has overall responsibility for clinical results from the suite of Promarker® diagnostic tests.

Go-to-Market optionality: Synergistic pathways

ASX: PIQ

Initial sales led by Direct to Consumer with option to expand through licencing

Direct to consumer (DTC) and digital marketing pathway



Traditional licensing model



Go-to-Market

ASX: PIQ

Direct to Consumer (DTC) digital solution implemented







- Launched in Australia in Q1 CY25
  - Automated immunoassay established
  - Clinical ISO 15189 certification pending
  - Blood collection logistics established
  - GP practices engaged
  - Integrated digital solution enacted

Patient journey & Revenue capture model

ASX: PIQ

Managed via a fully integrated digital solution @ www.myTEST.health



* Electronic Medical Record (EMR) integration – GP practice software via digital (HL7 compliant) interface

^ Unique to each practice; also guides GP clinic recognition in PI-Laboratory Information Management System (LIMS)

GP blast followed by relationship nurture workflows

ASX: PIQ

Comprehensive Customer Relationship Management (CRM) system established



Blast(s) to designated clinics (geographies, demographics, etc)
QR to video call to action



GP Requests eDetail ProD

GP Requests eDetail ProEso





GP outreach program

ASX: PIQ

Multiple contact points established for physician engagement



Market launch: Australia and USA

ASX: PIQ

	Australia	USA
PI Reference Laboratory	ISO 17025 established ISO 15189 pending	CLIA certification established
Initial capacity of laboratory	Promarker*D*: 84,000 pa Promarker*Eso*: 32,000 pa	Promarker*D*: 84,000 pa Promarker*Eso*: 32,000 pa
Launch Date	Promarker*D*: Q1 CY25 Promarker*Eso*: Q1 CY25	Promarker*D*: Q2 CY25 Promarker*Eso*: Q3 CY25
Proteomics retained test fee	>70% of test sale price	
Reimbursement	Self pay	Self pay & existing CMS code
Pricing	Promarker*D*: AUD $245 Promarker*Eso*: *tba* Promarker*Endo*: *tba*	PromarkerD: USD $391 Promarker*Eso*: *tba* Promarker*Endo*: *tba*
Market Size	Diabetes - 1.5 million Endometriosis - 1 in 9 women GERD (Esophageal Cancer) – 2 million	Diabetes - 32 million Endometriosis - 1 in 9 women GERD (Esophageal Cancer) – 66 million

Market launch: strategic rationale

ASX: PIQ

The Direct to Consumer route provides maximum optionality:

- Fastest and most cost-effective path to market
- Scalable with low cost of customer acquisition compared to traditional sales model
- Provides a platform to:
  - partner with virtual care providers in this fast-growing market
  - accelerate expansion to GP practices and primary care
  - partner with advocacy groups
- Reduces risk for partners as product already in market
- Leverage more attractive terms for out-licensing
- Digital solution is readily replicated across the Promarker tests
  - accelerates expansion into US market - tech transfers & marketing content ready to go

Multiple Value Drivers in H1 CY25

ASX: PIQ

Milestone	TARGET Qtr	Dec	Mar	Jun	Impact
Commercial					
US reference lab established			✓		Key to first US sales and reimbursement
First Sales PromarkerD in USA					Initiate pathway to significant revenues
Australian clinical lab certification established					
PromarkerD launched in Australia			✓		Drive global uptake and future revenue
PromarkerEndo launched in Australia					First sales
PromarkerEso launched in Australia					First sales
Clinical/Technical					
Endometriosis Dx - results update		✓			New first-in-class diagnostic test
Esophageal Cancer Dx - results update		✓			New first-in-class diagnostic test
OxiDx test - results update		✓			New first-in-class diagnostic test
Regulatory/Reimbursement					
PromarkerD PLA code (US) application			✓		Support US roll-out
Submit PromarkerD, Eso & Endo to TGA/FDA					Assist global roll-out

Summary – Exceptional Growth Opportunity

- **Disruptive, cutting-edge technology & proven in-house diagnostics platform**
- **Multiple patented tests**
  - PromarkerD test de-risked, patented, commercial launch ready
  - PromarkerEso, PromarkerEndo and OxiDx tests nearing market entry
  - Tests are scalable with high margins – and address large markets
- **Team, infrastructure and certifications in place to support commercial launches**
- **First sales in the first half of this year (H1 CY25)**

Contact

Dr Richard Lipscombe

Managing Director

T:+61 8 9389 1992

E: enquiries@proteomicsinternational.com

www.proteomicsinternational.com

Dirk van Dissel

Investor Relations

Candour Advisory

T:+61 408 326 367

E: dirk@candouradvisory.com.au

Proteomics International

LABORATORIES LTD

Supplemental – the Promarker® suite of diagnostic tests

The Need: Target Populations for DKD, Endo and Eso

ASX: PIQ

10.5% of the global adult population have diabetes



1 in 9 women have endometriosis

(currently screened by ultrasound or MRI and diagnosed by laparoscopy with biopsy)



1-2% of western populations at risk of esophageal cancer

(Gastroesophageal reflux disease (GERD) currently screened by endoscopy with biopsy)



Sources:
International Diabetes Federation (IDF) Atlas 10th Edition 2021 [Age group 20-79 years]
Endometriosis, World Health Organisation (WHO.org)
European Commission (StatisticsTimes)(ONS.gov)
www.cancer.org.au/assets/pdf/9-august-2020
www.yalemedicine.org/conditions/gerd-gastroesophageal-reflux-disease
www.racgp.org.au/afp/2015/october/gastro-oesophageal-reflux-disease-gord-in-australi

PromarkerD: Diabetic Kidney Disease

ASX: PIQ

Intellectual Property	Patents granted in all major jurisdictions - PromarkerD Patent family & Trademark covers **72%** of the world's diabetes patients
Regulatory	**CE Mark** (EU) registration received for the PromarkerD Immunoassay IVD US sales utilising Lab Developed Test (LDT) pathway via CLIA certified laboratories; Australia utilising ISO 15189 pathway
Manufacturing scale-up	ISO 13485 certified EU manufacturer Simple technology platform (immunoassay) – easy to use and integrate into existing pathology lab processes
Peer Reviewed	PromarkerD tested on over **5,000 patients** in 4-year clinical studies Global multi-centre clinical study (CANVAS) on 3,568 participants in collaboration with Janssen (J&J) Clinical & analytical validity proven (Sensitivity 86%); 10+ Peer Reviewed Publications
Physician Support	**Clinical utility demonstrated** - US based survey showed **96%** of physicians were likely to use PromarkerD test scores for clinical decision making; PromarkerD consistently ranked as one of the top 2 factors driving physician decision-making.
Outperforms Standard of Care	857 community-based patients tested for existing DKD at baseline: 497 had normal kidney function PromarkerD accurately predicted 84% (N=38); All were missed by Standard of Care tests
The Need	**Economic Cost**: Chronic Kidney Disease cost Australia A$9.9bn in 2021 (Kidney Health Australia) - investment in early detection could yield a net benefit of $10.2bn over 20 years; Kidney Research UK have declared a public health emergency - by 2033 kidney disease risks costing the UK economy £13.9bn annually
The Treatments	**New renal protective therapies:** SLGT2-inhibitors approved & potential use of GLP-1 agonist semaglutide (Ozempic) PromarkerD identifies patients for better management of diabetes, adherence to medications, and focus on diet & exercise
The Utility	**Complementary diagnostic** - Early diagnosis of DKD using PromarkerD can help inform doctors' treatment decisions to improve clinical outcomes for patients. Actions taken BEFORE the onset of DKD
Breakthrough Study	**PromarkerD validated for Type 1 (T1D) diabetes** - demonstrated **high accuracy** (AUC of 0.93) in predicting chronic kidney disease in patients with T1D (represents 10% of all diabetes cases); Offers a new target market



PromarkerEso: Esophageal Cancer

ASX: PIQ

First-in-class blood test 'PromarkerEso' ready for commercialisation

Clinical question – can a blood test distinguish between individuals who are:

1) **healthy**
2) **esophageal adenocarcinoma (EAC) patients**
   - Only 50% of EAC patients report chronic acid reflux
   - 90% of EAC cases continue to remain undetected
   - 25% of EAC cases misdiagnosed as negative by endoscopy

Test status

- **Test shows 94% accuracy** in diagnosing patients with and without the disease
  (World Congress Esophageal Diseases, 2024)
- Advanced statistical modelling being refined using 'traffic light' system to **improve test performance for clinical use**
- New clinical results **submitted for peer review publication**
- Methodology (mass spectrometry) being **adapted for clinical launch**
- **Patents granted in Europe, China, Australia**; USA pending
- Discussions underway to establish test in reference laboratories worldwide
- Proteomics International preparing **to launch PromarkerEso in Australia** under ISO 15189 accreditation, targeting **Q1 CY25**

A non-invasive blood test for esophageal cancer could transform the way this disease is detected and is attracting interest from world leaders in EAC treatment

Clinical studies

- *Development and Validation* - Collaboration with QIMR Berghofer Medical Research Institute analysed 302 samples across two patient cohorts: *(World Congress Esophageal Diseases, 2023)*
  - PROBE-NET study, Australia (N=249)
  - Ochsner Health System, USA (N=49)
- *Clinical validation* - biomarker panel confirmed in independent patient cohort from Victoria Cancer Biobank (N=165)
  (Lorne Proteomics Symposium, Feb '24)
- *Clinical validation* – analysis of samples from Victoria Cancer Biobank confirmed clinical performance of the test (N=165)
  (World Congress Esophageal Diseases, 2024)

PromarkerEndo: Endometriosis

ASX: PIQ

First-in-class blood test 'PromarkerEndo' nearing commercialisation

Clinical question – can a blood test distinguish between individuals who are:

1) **healthy**
2) **symptomatic patients (pelvic pain but surgically-diagnosed absence of endometriosis)**
3) **endometriosis patients (confirmed by laparoscopy – 4 stages: minimal/mild/moderate/severe)**

Test status

- **Excellent diagnostic performance published for prototype PromarkerEndo test in identifying all stages of endometriosis with high accuracy** *(Human Reproduction 2024)*
  - endo vs healthy controls: Sensitivity 96%, Specificity 98%
  - stage IV endo vs symptomatic controls: Sensitivity 98%, Specificity 96%
  - stage I endo vs symptomatic controls: Sensitivity 87%, Specificity 72%
- Advanced statistical modelling being finalised using 'traffic light' system to **improve test performance for clinical use**
- Methodology (mass spectrometry) being **adapted for clinical launch**
- **Patents pending** in all major jurisdictions
- Discussions underway to establish test in reference laboratories worldwide
- Proteomics International preparing to **launch PromarkerEndo in Australia** under ISO 15189 accreditation, targeting **Q2 CY25**

A non-invasive blood test for endometriosis is a potential 'game-changer' in women's health and the published results have attracted interest worldwide

Clinical studies

- *Development* - biomarker panel (Wesley Medical Research Biobank N=56 samples)
- *Validation* - Collaboration with Royal Women's Hospital & University of Melbourne analysed (endometriosis N=464; healthy individuals N=153; symptomatic controls N=132) *(World Endometriosis Conference, May '23)*
- *Confirmation results* - Peer reviewed and published *(Journal Human Reproduction, Dec 24)*
- *Further studies* - Collaboration ongoing with University of Oxford for international validation study (N=600 samples)

OxiDx: Oxidative Stress

ASX: PIQ

Groundbreaking blood test nearing commercialisation

What is Oxidative Stress?

- Oxidative stress occurs when the body's antioxidant defences are overwhelmed by an excess of toxic oxidants
- **Oxidative stress is implicated in over 70 health conditions** with levels often reflective of a person's health condition

OxiDx – blood test to monitor oxidative stress

- OxiDx P/L was spun out of PIQ and the University of Western Australia in Aug 2022

World first test:

- **Accurate** - highly sensitive
- **Simple to use** – finger prick sample
- **Cost effective** – for mass market use
- **Peer reviewed** – multiple journal publications
- **Patented** – patent families cover Australia & USA, Europe & Japan; others pending

OxiDx

Targeting commercial use of OxiDx technology:

- **Athletic monitoring tool for competition preparedness:**
  - **Professional Sports** – performance, recovery and injury risk management – *55% of sports injuries are muscle related*
    - World first results published showing **OxiDx test can identify muscle damage and assess recovery in elite athletes** *(Physiological Reports, Dec 2024)*
  - **Thoroughbred Racing Industry** – injury risk management and race-preparedness *- 85% of Thoroughbreds suffer injury in their first 2-3 yrs*
    - ***Proof-of-concept study being finalised***

New commercialisation pathways:

- Potential spin-out or partnering opportunity across sports & horse racing industries
- Proteomics International preparing to **launch OxiDx in Australia** under ISO 17025 accreditation, targeting **Q3 CY25**




Australian Institute of Health and Welfare | Appraising the Welfare of Thoroughbred Race horses in Training | doi: 10.1373/clinchem.2005.061408

Proteomics International (Est'd 2001)

ASX: PIQ

Identity

Proteomics International is a medical technology company specialising in predictive diagnostics and advanced analytical services using proteomics – the industrial scale study of the structure and function of proteins.

Mission

To improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

Vision

To help create a world where disease is detected early and cured simply.